{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:50:21Z","timestamp":1780368621130,"version":"3.54.1"},"reference-count":31,"publisher":"Becaris Publishing Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Risk of long-term care (LTC) admission (LTCA) associated with atypical antipsychotic (AAP) use among patients with Parkinson's disease psychosis (PDP) is a major concern. However, no comparative studies have examined the differences in risk of LTC admissions between pimavanserin (PIM), the only FDA-approved AAP for PDP, and other off-label AAPs including quetiapine (QUE).\n            <jats:bold>Objective:<\/jats:bold>\n            To examine all-cause LTCA rates and risk among PDP patients treated with AAPs such as QUE or PIM.\n            <jats:bold>Methods:<\/jats:bold>\n            Analysis of Parts A, B\u00a0and D claims (100% Medicare sample; 2013\u20132019) of Medicare beneficiaries with PDP that initiate \u226512-month continuous PIM or QUE monotherapy from 1 January 2014 to\u00a031 December 2018 (i.e., index date) without any AAP use in the 12-month pre-index period was conducted. Outcome assessments among 1:1 propensity score-matched (31 variables \u2013 age, sex, race, region and 27 Elixhauser comorbidities) beneficiaries on PIM versus QUE included risk of all-cause skilled nursing facility stays (SNF-stays), LTC-stays, and overall LTCA (i.e., SNF-stays or LTC-stays). All-cause LTCA rates and LTCA risk were compared using logistic regression and cox proportional hazards models, respectively, controlling for demographics, comorbidities and co-existing-dementia or insomnia.\n            <jats:bold>Results:<\/jats:bold>\n            Of the matched sample (n\u00a0=\u00a0842 for each group) from total sample (n\u00a0=\u00a09652), overall all-cause LTCA and SNF-stay rates were 23.2 and 20.2% for PIM versus 33.8 and 31.4% for QUE, respectively (p\u00a0&lt;\u00a00.05, for each). Hazard ratio (95% CI) for risk of SNF-stay and overall LTCA was 0.78 (0.61, 0.98) and 0.80 (0.66, 0.97), respectively, for PIM versus QUE beneficiaries (p\u00a0&lt;\u00a00.05, for each).\n            <jats:bold>Conclusion:<\/jats:bold>\n            The 20% lower risk of LTCA (i.e., greater delay) with PIM versus QUE in this analysis may suggest that PIM should be started early for the treatment of PDP.\n          <\/jats:p>","DOI":"10.57264\/cer-2023-0114","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T11:33:25Z","timestamp":1702640005000},"source":"Crossref","is-referenced-by-count":6,"title":["Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson's disease psychosis in USA: a retrospective administrative claims database analysis"],"prefix":"10.57264","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4878-0822","authenticated-orcid":false,"given":"Krithika","family":"Rajagopalan","sequence":"first","affiliation":[{"name":"Anlitiks Inc., FL\u00a034786, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-1234","authenticated-orcid":false,"given":"Nazia","family":"Rashid","sequence":"additional","affiliation":[{"name":"Medical Affairs, Acadia Pharmaceuticals Inc., CA\u00a092130, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilesh","family":"Doshi","sequence":"additional","affiliation":[{"name":"Medical Affairs, Acadia Pharmaceuticals Inc., CA\u00a092130, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41531-022-00410-y","article-title":"Incidence of Parkinson disease in North America","volume":"8","author":"Willis AW","year":"2022","unstructured":"Willis AW, Roberts E, Beck JC Incidence of Parkinson disease in North America. NPJ Parkinsons Dis. 8(1), 170 (2022).","journal-title":"NPJ Parkinsons Dis."},{"issue":"1","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jns.2014.10.033","article-title":"Cognitive correlates of hallucinations and delusions in Parkinson's disease","volume":"347","author":"Factor SA","year":"2014","unstructured":"Factor SA, Scullin MK, Sollinger AB Cognitive correlates of hallucinations and delusions in Parkinson's disease. J. Neurol. Sci. 347(1\u20132), 316\u2013321 (2014).","journal-title":"J. Neurol. Sci."},{"key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","article-title":"Prevalence of Parkinson's disease across North America","volume":"4","author":"Marras C","year":"2018","unstructured":"Marras C, Beck JC, Bower JH Prevalence of Parkinson's disease across North America. NPJ Parkinsons Dis. 4, 21 (2018).","journal-title":"NPJ Parkinsons Dis."},{"issue":"8","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1532-5415.2000.tb06891.x","article-title":"Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study","volume":"48","author":"Aarsland D","year":"2000","unstructured":"Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J. Am. Geriatr. Soc. 48(8), 938\u2013942 (2000).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"11","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","article-title":"Risk factors for nursing home placement in advanced Parkinson's disease","volume":"43","author":"Goetz CG","year":"1993","unstructured":"Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43(11), 2227\u20132229 (1993).","journal-title":"Neurology"},{"issue":"5","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1212\/WNL.0000000000001715","article-title":"Nursing home and end-of-life care in Parkinson disease","volume":"85","author":"Safarpour D","year":"2015","unstructured":"Safarpour D, Thibault DP, DeSanto CL Nursing home and end-of-life care in Parkinson disease. Neurology 85(5), 413\u2013419 (2015).","journal-title":"Neurology"},{"key":"e_1_3_8_9_2","first-page":"100143","article-title":"Long-term outcomes with pimavanserin for psychosis in clinical practice","volume":"6","author":"Akbar U","year":"2022","unstructured":"Akbar U, Friedman JH. Long-term outcomes with pimavanserin for psychosis in clinical practice. Clin. Park. Relat. Disord. 6, 100143 (2022).","journal-title":"Clin. Park. Relat. Disord."},{"issue":"10","key":"e_1_3_8_10_2","first-page":"S199","article-title":"Parkinson's disease psychosis: symptoms, management, and economic burden","volume":"21","author":"Hermanowicz N","year":"2015","unstructured":"Hermanowicz N, Edwards K. Parkinson's disease psychosis: symptoms, management, and economic burden. Am. J. Manag. Care. 21(Suppl. 10), S199\u2013S206 (2015).","journal-title":"Am. J. Manag. Care."},{"issue":"1","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1017\/S1041610205221026","article-title":"Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cosh? Argument","volume":"17","author":"Ballard C","year":"2005","unstructured":"Ballard C, Cream J. Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cosh? Argument. Int. Psychogeriatr. 17(1), 4\u201329 (2005).","journal-title":"Int. Psychogeriatr."},{"issue":"1","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40801-021-00284-1","article-title":"Falls and fractures in patients with Parkinson's disease-related psychosis treated with pimavanserin vs atypical antipsychotics: a cohort study","volume":"9","author":"Layton JB","year":"2022","unstructured":"Layton JB, Forns J, Turner ME Falls and fractures in patients with Parkinson's disease-related psychosis treated with pimavanserin vs atypical antipsychotics: a cohort study. Drugs Real World Outcomes. 9(1), 9\u201322 (2022).","journal-title":"Drugs Real World Outcomes."},{"issue":"5","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamaneurol.2016.0031","article-title":"Association of antipsychotic use with mortality risk in patients with Parkinson disease","volume":"73","author":"Weintraub D","year":"2016","unstructured":"Weintraub D, Chiang C, Kim HM Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol. 73(5), 535\u2013541 (2016).","journal-title":"JAMA Neurol."},{"key":"e_1_3_8_14_2","unstructured":"Acadia Pharmaceuticals. Nuplazid\u00ae (Pimavanserin) Prescribing Information. Acadia Pharmaceuticals Inc CA USA (2018)."},{"issue":"10","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40265-016-0597-9","article-title":"Pimavanserin: first global approval","volume":"76","author":"Markham A","year":"2016","unstructured":"Markham A. Pimavanserin: first global approval. Drugs 76(10), 1053\u20131057 (2016).","journal-title":"Drugs"},{"issue":"9916","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled Phase 3 trial [published correction appears in Lancet 384(9937), 28 (2014)]","volume":"383","author":"Cummings J","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R Pimavanserin for patients with Parkinson's disease psychosis: a randomized, placebo-controlled Phase 3 trial [published correction appears in Lancet 384(9937), 28 (2014)]. Lancet. 383(9916), 533\u2013540 (2014).","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_8_17_2","first-page":"46","article-title":"Pimavanserin in the treatment of Parkinson's disease psychosis: meta-analysis and meta-regression of randomized clinical trials","volume":"19","author":"Mansuri Z","year":"2022","unstructured":"Mansuri Z, Reddy A, Vadukapuram R, Trivedi C, Amara A. Pimavanserin in the treatment of Parkinson's disease psychosis: meta-analysis and meta-regression of randomized clinical trials. Innov. Clin. Neurosci. 19(1\u20133), 46\u201351 (2022).","journal-title":"Innov. Clin. Neurosci."},{"issue":"1","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/13696998.2022.2152600","article-title":"Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics","volume":"26","author":"Rajagopalan K","year":"2023","unstructured":"Rajagopalan K, Rashid N, Kumar S, Doshi D. Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics. J. Med. Econ. 26(1), 34\u201342 (2023).","journal-title":"J. Med. Econ."},{"issue":"2","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1176\/ajp.151.2.237","article-title":"HIV-associated psychosis: a study of 20 cases","volume":"151","author":"Sewell DD","year":"1994","unstructured":"Sewell DD, Jeste DV, Atkinson JH HIV-associated psychosis: a study of 20 cases. Am. J. Psychiatry 151(2), 237\u2013242 (1994).","journal-title":"Am. J. Psychiatry"},{"key":"e_1_3_8_20_2","article-title":"Mental health and substance abuse issues among people with HIV","author":"Beckett MK","year":"2007","unstructured":"Beckett MK, Collins RL, Burnam MA Mental health and substance abuse issues among people with HIV. Lessons from HCSUS www.rand.org\/pubs\/research_briefs\/RB9300.html (2007).","journal-title":"Lessons from HCSUS"},{"key":"e_1_3_8_21_2","unstructured":"Substance Abuse and Mental Health Services Administration. Co-occurring disorders and other health conditions. www.samhsa.gov\/medication-assisted-treatment\/medications-counseling-related-conditions\/co-occurring-disorders (2022)."},{"issue":"4","key":"e_1_3_8_22_2","first-page":"338","article-title":"Integrating care for people with co-occurring alcohol and other drug, medical, and mental health conditions","volume":"33","author":"Sterling S","year":"2011","unstructured":"Sterling S, Chi F, Hinman A. Integrating care for people with co-occurring alcohol and other drug, medical, and mental health conditions. Alcohol Res. Health. 33(4), 338\u2013349 (2011).","journal-title":"Alcohol Res. Health."},{"key":"e_1_3_8_23_2","volume-title":"Performing a 1: N case-control match on propensity score [computer program]","year":"2004","unstructured":"Performing a 1: N case-control match on propensity score [computer program]. SAS Institute, Montreal, Canada (2004)."},{"key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2147\/NDT.S201029","article-title":"Atypical antipsychotics for Parkinson's disease psychosis: a systematic review and meta-analysis","volume":"15","author":"Zhang H","year":"2019","unstructured":"Zhang H, Wang L, Fan Y Atypical antipsychotics for Parkinson's disease psychosis: a systematic review and meta-analysis. Neuropsychiatr. Dis. Treat. 15, 2137\u20132149 (2019).","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"5","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s12325-022-02075-8","article-title":"Comparative outcomes of commonly used off-label atypical antipsychotics in the treatment of dementia-related psychosis: a network meta-analysis","volume":"39","author":"Yunusa I","year":"2022","unstructured":"Yunusa I, Rashid N, Demos GN, Mahadik BS, Abler VC, Rajagopalan K. Comparative outcomes of commonly used off-label atypical antipsychotics in the treatment of dementia-related psychosis: a network meta-analysis. Adv. Ther. 39(5), 1993\u20132008 (2022).","journal-title":"Adv. Ther."},{"issue":"5","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/08919887231154933","article-title":"Comparative efficacy, safety, and acceptability of pimavanserin and other atypical antipsychotics for Parkinson's disease psychosis: systematic review and network meta-analysis","volume":"36","author":"Yunusa I","year":"2023","unstructured":"Yunusa I, Rashid N, Seyedin R, Paratane D, Rajagopalan K. Comparative efficacy, safety, and acceptability of pimavanserin and other atypical antipsychotics for Parkinson's disease psychosis: systematic review and network meta-analysis. J. Geriatr. Psychiatry Neurol. 36(5), 417\u2013432 (2023).","journal-title":"J. Geriatr. Psychiatry Neurol."},{"issue":"11","key":"e_1_3_8_27_2","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/jgs.13702","article-title":"American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults","volume":"63","author":"American Geriatrics Society 2015 Beers Criteria Update Expert Panel","year":"2015","unstructured":"American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 63(11), 2227\u20132246 (2015).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"2","key":"e_1_3_8_28_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review [published correction appears in Mov. Disord. 34(5), 765 (2019)]","volume":"34","author":"Seppi K","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review [published correction appears in Mov. Disord. 34(5), 765 (2019)]. Mov. Disord. 34(2), 180\u2013198 (2019).","journal-title":"Mov. Disord."},{"issue":"8","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1176\/appi.ajp.20220519","article-title":"The safety of pimavanserin for Parkinson's disease and efforts to reduce antipsychotics for people with dementia","volume":"179","author":"Schneider LS","year":"2022","unstructured":"Schneider LS. The safety of pimavanserin for Parkinson's disease and efforts to reduce antipsychotics for people with dementia. Am. J. Psychiatry 179(8), 519\u2013521 (2022).","journal-title":"Am. J. Psychiatry"},{"issue":"13","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"e1266","DOI":"10.1212\/WNL.0000000000012601","article-title":"Risk of hospitalization and death associated with pimavanserin use in older adults with Parkinson disease","volume":"97","author":"Hwang YJ","year":"2021","unstructured":"Hwang YJ, Alexander GC, An H, Moore TJ, Mehta HB. Risk of hospitalization and death associated with pimavanserin use in older adults with Parkinson disease. Neurology 97(13), e1266\u2013e1275 (2021).","journal-title":"Neurology"},{"issue":"8","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1176\/appi.ajp.21090876","article-title":"Mortality among Parkinson's disease patients treated with pimavanserin or atypical antipsychotics: an observational study in Medicare beneficiaries","volume":"179","author":"Mosholder AD","year":"2022","unstructured":"Mosholder AD, Ma Y, Akhtar S Mortality among Parkinson's disease patients treated with pimavanserin or atypical antipsychotics: an observational study in Medicare beneficiaries. Am. J. Psychiatry 179(8), 553\u2013561 (2022).","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"e_1_3_8_32_2","first-page":"785","article-title":"Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis","volume":"27","author":"Brown JD","year":"2021","unstructured":"Brown JD, Cicali B, Henriksen C, Malaty I, Okun MS, Armstrong MJ. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis. J. Manag. Care Spec. Pharm. 27(6), 785\u2013790 (2021).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"10","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/brainsci12101286","article-title":"Pimavanserin and Parkinson's disease psychosis: a narrative review","volume":"12","author":"Rissardo JP","year":"2022","unstructured":"Rissardo JP, Durante \u00cd, Sharon I, Fornari Caprara AL. Pimavanserin and Parkinson's disease psychosis: a narrative review. Brain Sci. 12(10), 1286 (2022).","journal-title":"Brain Sci."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T11:37:55Z","timestamp":1704454675000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.57264\/cer-2023-0114"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0114","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"e230114"}}